论文部分内容阅读
目的研究宫颈癌患者血清可溶性Endoglin水平变化及其临床价值。方法应用酶联免疫吸附试验法(ELISA)对31例正常人(正常对照组)及63例宫颈癌患者(宫颈癌组)血清可溶性Endoglin水平进行检测,并比较38例宫颈癌患者根治手术前后血清可溶性Endoglin水平。结果宫颈癌组患者血清可溶性Endoglin水平(5.01±1.03)μg/L明显高于正常对照组(3.57±0.30)μg/L(P<0.01),血清可溶性Endoglin水平与宫颈癌患者临床分期有明显相关,与宫颈癌组患者年龄和病理类型无明显相关;Ⅳ期宫颈癌血清可溶性Endoglin水平(6.41±0.22)μg/L明显高于Ⅲ期(5.25±0.25)μg/L(P<0.01),Ⅲ期血清可溶性Endoglin水平明显高于Ⅱ期(4.38±0.26)μg/L(P<0.01),Ⅱ期血清可溶性Endoglin水平明显高于Ⅰ期(3.68±0.29)μg/L(P<0.05),Ⅰ期血清可溶性Endoglin水平与正常对照组比较,差异无统计学意义(P>0.05),血清可溶性Endoglin在宫颈癌患者根治术后的表达水平(3.85±0.71)μg/L明显低于术前(4.38±0.68)μg/L(P<0.01)。结论血清可溶性Endoglin表达水平可作为反映宫颈癌患者病情、疗效判断和预后评价的一个参考指标。
Objective To study the changes of serum soluble Endoglin levels in patients with cervical cancer and its clinical value. Methods Serum soluble Endoglin levels were measured in 31 normal subjects (control group) and 63 cervical cancer patients (cervical cancer group) by enzyme-linked immunosorbent assay (ELISA). The serum levels of endoglin in 38 patients with cervical cancer before and after radical surgery Soluble Endoglin levels. Results The level of serum Endoglin in patients with cervical cancer was significantly higher than that in healthy controls (5.01 ± 1.03 μg / L vs 3.57 ± 0.30 μg / L, P <0.01). Serum endoglin levels were significantly correlated with clinical stage (6.41 ± 0.22) μg / L in stage Ⅳ cervical cancer was significantly higher than that in stage Ⅲ (5.25 ± 0.25) μg / L (P <0.01), while the level of Ⅲ The level of soluble endoglin in stage Ⅱ was significantly higher than that in stage Ⅱ (4.38 ± 0.26) μg / L (P <0.01), and the level of endoglin in stage Ⅱ was significantly higher than that in stage Ⅰ (3.68 ± 0.29) μg / L The serum endoglin level in patients with cervical cancer was significantly lower than that in the control group (3.85 ± 0.71) μg / L after the end of treatment (P> 0.05) ± 0.68) μg / L (P <0.01). Conclusion Serum soluble Endoglin expression level can be used as a reference index to reflect the condition, judgment of curative effect and prognosis of patients with cervical cancer.